


PHARMACEUTICAL 2022

OPIANT PHARMACEUTICALS INC. Rank 44 of 475







PHARMACEUTICAL 2022



OPIANT PHARMACEUTICALS INC. Rank 44 of 475



The relative strengths and weaknesses of OPIANT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OPIANT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 420% points. The greatest weakness of OPIANT PHARMACEUTICALS INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 412% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	69,159
Cost of Goods Sold	0
Intangible Assets	12
Liabilities, Current	6,846
Liabilities, Non-Current	673
Other Assets	1,179
Other Compr. Net Income	-28
Other Expenses	13,667
Other Liabilities	16,069
Other Net Income	-2,123
Property and Equipment	78
Research and Development	16,834
Revenues	47,785
Selling, General and Administrative Expense	12,153

Output Variable	Value in 1000 USD
Assets	70,428
Liabilities	23,588
Expenses	42,653
Stockholders Equity	46,840
Net Income	3,009
Comprehensive Net Income	2,995
Economic Capital Ratio	135%